Degree Type

Creative Component

Semester of Graduation

Fall 2019

Department

Biomedical Sciences

First Major Professor

Dr. Jonathan Mochel

Degree(s)

Master of Science (MS)

Major(s)

Biomedical Sciences

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an emerging cancer treatment option throughout the world. This approach to cancer treatment uses a patient’s own immune cells and engineers them to directly target and kill cancer that has been evading their immune system. There has been much success when using CAR T-cell therapy in hematological malignancies due to the almost universal expression of the CD19 antigen. Though this success has not translated into success with solid tumors, there has been extensive research to improve the results. Solid tumors pose as a more difficult target due to their variable expression of target antigens, difficulty to penetrate, and hostile microenvironment. These challenges have been investigated and tested to improve CAR T-cell therapy success in the future.

Copyright Owner

Parris, Austin

File Format

Word

Share

COinS